Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Phase 1 Drug Interaction Study of Suramin and Warfarin in Patients With Prostate Cancer

Meyer, Mark, Pharm.D.; Jeong, Erwin, Pharm.D.; Bolinger, Barbara, Pharm.D.; Chen, Liang, Ph.D.; Lenehan, Peter, M.D., Ph.D.; Slichenmyer, William, M.D.; Natale, Ronald B., M.D.

American Journal of Clinical Oncology: April 2001 - Volume 24 - Issue 2 - p 167-171
Articles
Buy

Potential interaction between suramin and warfarin was evaluated when coadministered to patients with cancer. Thirteen men with advanced hormone-refractory prostate cancer were initially stabilized with warfarin to a prothrombin time (PT) of 2 ± 0.2 International Normalized Ratio (INR) during a lead-in period of 4 weeks. A baseline daily warfarin dose was established, and treatment with suramin plus hydrocortisone was then started. The effect of suramin on the anticoagulant activity of warfarin was assessed in each patient by comparing his baseline warfarin dose with average daily doses required to maintain the same INR level over each of the initial 6 weeks of a 12-week course of suramin treatment. The average daily dose of warfarin required to maintain PT at 2 ± 0.2 INR decreased from a baseline value of 4.2 to between 3.4 and 4.0 during the 6 weeks of suramin plus warfarin treatment. Despite failing to demonstrate equivalence applying a 90% confidence interval approach, required reductions in warfarin dose were clinically minor and the combination was well tolerated. Based on these results, the eligibility criteria for a large ongoing randomized study were amended to allow entry of men receiving warfarin therapy. This interaction study, together with experience gained in a larger trial setting, has confirmed that warfarin and suramin can be safely coadministered, provided that coagulation status is appropriately monitored.

From Pfizer Global Research and Development, Ann Arbor Laboratories (M.M., B.B., L.C., P.L., W.S.), Ann Arbor, Michigan; University of Southern California, Norris Cancer Center (E.J., B.B.), Los Angeles, California; and Cedars-Sinai Comprehensive Cancer Center (R.B.N.), Los Angeles, California, U.S.A.

Supported by Parke-Davis Pharmaceutical Research Division, Warner-Lambert Company.

Address correspondence and reprint requests to Mark Meyer, Senior Associate Director–Oncology, Pfizer Global Research and Development, Ann Arbor, MI 48105, U.S.A. E-mail: Mark.Meyer@Pfizer.com

© 2001 Lippincott Williams & Wilkins, Inc.